Gilead's Lurking Megablockbuster Drug

This episode of The Motley Fool's Market Checkup is dedicated to the world's largest pure play biotech stock, Gilead Sciences  (NASDAQ: GILD  ) . Market Checkup gives a full examination of Gilead's second-quarter results, takes a closer look at the company's current product portfolio, and analyzes the future drugs that have investors excited about the stock's future.

In this video, health care analysts David Williamson and Max Macaluso drill down on Gilead's strong drug development pipeline. Watch and find out why investors should be excited about Gilead's diversification into hepatitis-C treatments and why a drug currently under FDA review is poised to become a megablockbuster.

Your financial health is just as important as your personal health. The Motley Fool's special free report "3 Stocks That Will Help You Retire Rich" names specific investment opportunities that could help you build long-term wealth and help you retire well. The Fool also outlines critical wealth-building strategies that every investor should know. Click here to keep reading.

Follow David on Twitter: @MotleyDavid.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2632236, ~/Articles/ArticleHandler.aspx, 7/29/2014 9:07:03 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement